Verywell Health on MSN23h
HIV vs. AIDS: How They Differ and Why Early Treatment Matters
People with AIDS also have HIV, as HIV is the first stage of AIDS. Learn about the differences, how the conditions overlap, ...
The Trump Administration's HIV Prevention Contradictions
The new head of the Department of Health and Human Services (HHS), Robert F. Kennedy, Jr., has expressed some doubts about ...
Simulation model shows potential affordability of preventive HIV therapy for infants
HIV infections are lifelong and can weaken the immune system, causing a patient to be more susceptible to infection and ...
Immune response may be harnessed to control HIV, primary trial results suggest
Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...
Rolling Out5d
5 crucial reasons not to delay HIV treatment
Discover why starting HIV treatment promptly preserves immune function, prevents transmission, improves quality of life and reduces costs ...
Federal funding cuts threaten Colorado’s plan to reduce HIV infections
The Colorado Department of Public Health and Environment projected that new HIV diagnoses will total 482 in 2024 — virtually ...
technologynetworks9d
New Method Identifies Hidden Immune Cells That Harbor HIV
The findings were published in Nature Communications on March 6. HIV is a virus that attacks cells in the body fighting off ...
MedPage Today on MSN12d
Broadly Neutralizing Antibodies Delayed Rebound in HIV Patients Who Stopped ART
SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...
US biochemist researching treatment of HIV and coronaviruses wins Israel's Wolf Prize
Her research focuses on how the immune system identifies invading pathogens. She has broken ground, the fund said, in how ...
Healio13d
Two more people potentially cured of HIV
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...